Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
1.200
+0.010 (0.84%)
At close: Mar 9, 2026, 4:00 PM EDT
1.210
+0.010 (0.83%)
After-hours: Mar 9, 2026, 6:37 PM EDT
Soligenix Employees
As of December 31, 2024, Soligenix had 16 total employees, including 14 full-time and 2 part-time employees. The number of employees increased by 1 or 6.67% compared to the previous year.
Employees
16
Change (1Y)
1
Growth (1Y)
6.67%
Revenue / Employee
n/a
Profits / Employee
-$698,222
Market Cap
12.10M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 61 |
| CytoMed Therapeutics | 43 |
| BioLineRx | 28 |
| BioCardia | 20 |
| CalciMedica | 15 |
| NewcelX | 15 |
| Cellectar Biosciences | 11 |
| Akari Therapeutics, | 9 |
SNGX News
- 11 days ago - Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease - PRNewsWire
- 13 days ago - Soligenix to Present at BIO Investment & Growth Summit - PRNewsWire
- 25 days ago - Soligenix Details Recent Progress and Upcoming Milestones - PRNewsWire
- 2 months ago - Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) - PRNewsWire
- 2 months ago - Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel - Benzinga
- 2 months ago - Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis - PRNewsWire
- 3 months ago - Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space - GlobeNewsWire
- 3 months ago - Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire